Psychiatr. praxi. 2022;23(1):e17-e27 [Prakt. lékáren. 2021; 17(4): 207-212]

Treatment of anxiety disorders

Ivana Tašková
Psychiatrická nemocnice Bohnice, Praha
Ústav aplikované farmacie, Farmaceutická fakulta Masarykovy univerzity, Brno

Anxiety disorders are a very frequent group of mental disorders. Up to 15 % of the population experience some type of anxiety disorder during their lifetime. The most common types of anxiety disorders include social phobia, panic disorder, generalized anxiety disorder, mixed anxiety depressive disorder, agoraphobia, specific phobias, and post­‑traumatic stress disorder. Anxiety therapy should be comprehensive. Along with pharmacotherapy, psychotherapy plays essential role here. Anxiolytics are used for the treatment of anxiety disorders. The spectrum of anxiolytic drugs includes antidepressants, benzodiazepines, non­‑benzodiazepine anxiolytics, sedative antihistamines, some of the antiepileptics, or antipsychotics and beta­‑blockers. Their effectiveness varies according to the type of anxiety disorder. SSRI antidepressants are usually the drugs of choice in the treatment of anxiety. An anxious patient requires sensitive communication when dispensing the drug in pharmacy. Emphasis should be placed on compliance support, education about individual psychotropic drugs and warning of the dependence potential of benzodiazepines.

Keywords: anxiety disorders, pharmacotherapy, antidepressants, dispensation.

Published: April 8, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tašková I. Treatment of anxiety disorders. Psychiatr. praxi. 2022;23(1):e17-27.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Semple D, Smyth R. Oxford Handbook of Psychiatry. 3. vydání. Oxford: Oxford University Press 2013. ISBN 978-0-19-969388-7.
    2. Mohr P et al. Klinická psychofarmakologie. Praha: Maxdorf jessenius 2017. ISBN 978-80-7345-546-0.
    3. Vobořilová V, Červený R. Úzkostné poruchy. Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře 2018. Dostupné na: https://www.svl.cz/files/files/Doporucene­‑postupy/2017/DP­‑Uzkostne­‑poruchy.pdf
    4. Prašková H, Praško J. Farmakoterapie úzkostných poruch. Remedia. 2005; 15(6): 495-508.
    5. Orel M, kol. Psychopatologie (2012). 1. vydání. Praha: Grada. ISBN 978-80-247-3737-9.
    6. Raboch J, kol. Doporučené postupy psychiatrické péče IV. Psychiatrické společnosti ČLS JEP. 2014. ISBN 978-80-260-5792-5.
    7. Tašková I, kol. Psychofarmaka v kazuistikách. 1. vydání. Praha: Maxdorf Jesenius 2021. ISBN 978-80-7245-678-8
    8. Racková S, Janů L. Farmakoterapie úzkostných stavů. Psychiatrie pro praxi. 2006; 3: 112-116.
    9. Stahl S. Stahl's Essential Psychopharmacology - Neuroscientific Basis and Practical Applications. 4. vydání. Cambridge: Cambridge University Press 2016. ISBN 978-1-107-68646-5.
    10. Hubeňák J. Trazodon jedenkrát denně v léčbě deprese. Psychiatrie pro praxi. 2019; 20(3): 133-135 Go to original source...
    11. Kamphuis J, Taxis K, Schuiling­‑Veninga CC et al. Off­‑Label Prescriptions of Low­‑Dose Quetiapine and Mirtazapine for Insomnia in The Netherlands. Journal of Clinical Psychopharmacology. 2015; 35(4): 468-470. doi: 10.1097/JCP.0000000000000338. Go to original source... Go to PubMed...
    12. Taylor D et al. The Maudsley Prescribing Guidelines in Psychiatry, 13. vydaní. London: Wiley Blackwell 2018.
    13. Airagnes G et al. Benzodiazepine misuse in eldery: risk factors, consequences and management. Curr Psychiatry Rep. 2016; 18(10): 89. Go to original source... Go to PubMed...
    14. Schatzberg AF et al. Essential of Clinical Psychopharmacology 3. vydání. Washington: American Psychiatric Publishing 2013. ISBN 978-1-58562-419-5.
    15. Höschl C. Blokáda 5-HT2 receptorů a inhibice reuptake serotoninu- fyziologie, farmakologie a klinické důsledky. 47. Česko­‑Slovenská psychofarmakologická konference v Jeseníku, 5.-9. 1. 2005. Psychiatrie, 9, 2005; S1: 54.
    16. Lader M. Withdrawing benzodiazepines in patients with anxiety disorders. Curr Psychiatry Rep. 2016; 18: 8. Go to original source... Go to PubMed...
    17. Stein MB. Pharmacotherapy for social anxiety disorders in adults. Uptodate. 2021. Dostupné na: www.uptodate.com
    18. El­‑Mallakh P, Findlay J. Strategies to improve medication adherence in patients with schizophrenia: the role of support services. Neuropsychiatric Disease and Treatment. 2015; 11: 1077-1090. Go to original source... Go to PubMed...
    19. Češková E. Kombinace antidepresiv v léčbě deprese: doporučení a klinická praxe. Čes a slov Psychiat. 2015; 111(1): 33-36.
    20. Palanyiappan L, Insole L, Ferrier N. Combining antidepressants: a review of evidence. Advances in Psychiatric Treatment [online]. 2009; 15(2): 90-99. doi: 10.1192/apt.bp.107.004820. ISSN 1355-5146. Dostupné z: https://www.cambridge.org/core/product/identifier/S1355514600005460/type/journal_article. Go to original source...
    21. Tašková I, Langmaierová K. Psychiatrické minimum pro farmaceuty. Prakt. Lékáren. 2020; 16(1): 17-20. Go to original source...
    22. Stein MB. COVID-19: Psychiatric illness. Uptodate. 2021. Dostupné na: www.uptodate.com
    23. Mikkelsen ME, Abramoff B. Evaluation and management of adults following acute viral illness. Uptodate. 2021. Dostupné na: www.uptodate.com.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.